Novartis unveils 'US-first' strategy ahead of Sandoz spinoff

Nicole DeFeudis

Editor

Weeks after announcing the spinoff of generics arm Sandoz, Vas Narasimhan paints a picture of the new, slimmer Novartis — with a “US-first mindset,” he said …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novartis unveils 'US-first' strategy ahead of Sandoz spinoff

Nicole DeFeudis

Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Pfizer hires ex-FDA deputy Patrizia Cavazzoni as chief medical officer

Pfizer wants in on Summit’s goal to beat Keytruda via ADC combos

Post-Hoc: Pharma CEOs' alternative reality with Trump

Sanofi, Teva bolster case for IBD drug with Phase 2 data, despite potential competition

FDA lifts hold on Entrada's Duchenne drug after two years

How AI can address ongoing challenges in the life sciences industry

No­var­tis un­veils 'US-first' strat­e­gy ahead of San­doz spin­off

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Novartis unveils 'US-first' strategy ahead of Sandoz spinoff